Tesamorelin
Also known as: Egrifta
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Who's worth your money for Tesamorelin
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 28 scored sellers
$67.99 · 20mg · 99.8% purity
Best value
Lowest $/mg among scored sellers
$700 · 200mg · 98.9% purity
Most tested
28 independent COAs on file
$898 · 200mg · 99.8% purity
Average price
$8.68/mg
Sellers
88
45-day trend
-19.1%
76 of 88 sellers have a current price· 21 stale hidden· 27 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 23h ago
$3.40/mg -60.8% vs avg$67.99
20mg
- 🇺🇸 Peptide Partners99
via Disclosed Labs · 23h ago
$4.49/mg -48.3% vs avg$898
200mg
- 🇺🇸 Moglabs96
via Disclosed Labs · 23h ago
$10.00/mg +15.2% vs avg$50.00
5mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · 23h ago
$15.00/mg +72.8% vs avg$150
10mg
- 🇺🇸 Reta One Labs95
✓ verified at source · 23h ago
$3.90/mg -55.1% vs avg$39.00
10mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$5.45/mg -37.2% vs avg$109
20mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 23h ago
$6.00/mg -30.9% vs avg$60.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 23h ago
$8.00/mg -7.9% vs avg$79.99
10mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 23h ago
$76.50/mg +781.2% vs avg$765
10mg
- 🇺🇸 Forge Performance Co.94
✓ verified at source · 23h ago
$6.00/mg -30.9% vs avg$60.00
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tesamorelin
Get one email when the market actually moves — no newsletter, no noise.
About Tesamorelin
CAS
218949-48-5
Molecular formula
C221H366N72O67S
Sequence
YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL
Typical dose range
2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC
Half-life
~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)
COAs for Tesamorelin
260 third-party tests across 38 vendors. Each card links to the full report.
For
Tesamorelin
by NG Peptide· batch TSM-13
For
Tesamorelin
by Optima Supply· batch OS-2026-1763
For
Tesamorelin
by Hydro Research Peptides· batch HR-2026-4509
For
Tesamorelin
by NG Peptide· batch tsm20-04
For
Tesamorelin
by Profound Aminos· batch Black Cap
For
Tesamorelin
by Peptide Partners· batch TES202607
For
Tesamorelin
by Voltera Sciences· batch TSM10-06022026
For
Tesamorelin
by Peptide Plugs· batch 136-02-SM-WT
For
Tesamorelin
by Blank Peptides· batch B-3699671-P
For
Tesamorelin
by Voltera Sciences· batch TSM10.05.28.26
For
Tesamorelin
by Verified Peptides· batch TM07261020J
For
Tesa
by Ion Peptide· batch TSM10-06022026
For
Tesamorelin
by Peptide Partners· batch SPL-3947
For
Tesamorelin
by OROS Research· batch OR-LPTES5-526-B6
For
Tesamorelin
by Ion Peptide· batch TSM20-05142026
For
Tesamorelin
by Glacier Aminos· batch TES10GA-07
For
Tesamorelin
by Crush Research· batch CR-TSM20-0307-1
For
Tesamorelin
by Skye Peptides· batch TESA26-10-002
For
Tesamorelin
by Skye Peptides· batch TESA26-20-004
For
Tesamorelin/Ipamorelin
by Licensed Peptides· batch Green Cap
For
Tesamorelin
by NG Peptide· batch TSM20-3
For
Tesamorelin
by Forge Performance Co.· batch Clear Blue Cap
For
Tesamorelin
by Ion Peptide· batch TSM10-05042026
For
Tesamorelin
by Ion Peptide· batch TSMH10-0504206
23 citations indexed for Tesamorelin
Study · 2026
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.
case-report · 2026
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).
animal · 2026
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.
meta-analysis · 2026
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.
review · 2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
Study · 2026